natgillin/translations-raw huggingface dataset:
Study CAC-002-01, (An open-label, single-centre, nonrandomized continuation study of cholic acid capsules in subjects with inborn errors of bile acid synthesis), was the continuation of study CAC-91- 10-10 and started on 1 Jan 2010.
Ispitivanje CAC-002-01 (otvoreno, monocentrično, nerandomizirano nastavljajuće ispitivanje kapsula kolatne kiseline u ispitanika s prirođenim greškama u sintezi žučne kiseline) predstavlja nastavak ispitivanja CAC-91-10-10 i započeto je na 1. siječnja 2010. godine.
Study CLDT600A2303 - Clinical results over 208 weeks
Ispitivanje CLDT600A2303 – klinički rezultati tijekom 208 tjedana
Study CLDT600A2303 included HBeAg-positive patients from studies NV-02B-007 (GLOBE) or NV-02B-015 for off-treatment follow up.
Ispitivanje CLDT600A2303 uključivalo je praćenje HBeAg-pozitivnih bolesnika iz ispitivanja NV- 02B-007 (GLOBE) ili NV-02B-015 u periodu bez liječenja.
Study CLDT600A2303 was an open-label 104-week extension study in patients with compensated chronic hepatitis B who were previously treated with telbivudine for 2 years including patients from studies NV-02B-007 (GLOBE) and NV-02B-015, providing efficacy and safety data after 156 and 208 weeks of continuous telbivudine therapy.
Bolesnici s kompenzirajućim kroničnim hepatitisom B koji su prethodno liječeni telbivudinom tijekom 2 godine, uključujući bolesnike iz ispitivanja NV-02B (GLOBE) i NV-02B-015, obuhvaćeni su proširenim, otvorenim ispitivanjem CLDT600A2303 iz kojeg su proizašli podaci o sigurnosti i djelotvornosti terapije telbivudinom tijekom 156 i 208 tjedana.
Study CLDT600ACN04E1 - Impact of treatment on liver histology
Ispitivanje CLDT600ACN04E1 – učinak liječenja na histološki nalaz jetre
Study Cohorts
Kohorte u ispitivanju
Study conducted in HIV infected
Ispitivanje provedeno u bolesnika s
Study conducted in patients with chronic HCV infection
Ispitivanje je provedeno u bolesnika s kroničnom infekcijom HCV-om.
Study CV181013: add-on to TZD (n=183)
Ispitivanje CV181057: dodatak inzulinu
Study CV181014 (n=186)
Ispitivanje CV181014 (n=186)
Study CV181014: add-on to metformin
Ispitivanje CV181014: dodatak metforminu (n=186)
Study CV181057: add-on to insulin
Ispitivanje CV181057: dodatak inzulinu
Study D1050229
Ispitivanje D1050229
Study D1050231
Ispitivanje D1050231
Study D1050233
Ispitivanje D1050233
Study D1680L00006 (n=257) 8.4 -0.7 -0.7 (-0.9, -0.5) 2
Ispitivanje D1680L00006 (n=257) 8,4 -0,7 -0,7 (-0,9, -0,5)2
Study D2301 (FREEDOMS) was a 2- year placebo-controlled clinical study in 854 patients treated with fingolimod (placebo: 418).
Ispitivanje D2301 (FREEDOMS) bilo je dvogodišnje placebom kontrolirano kliničko ispitivanje u 854 bolesnika liječenih fingolimodom (placebo: 418).
Study D2309 (FREEDOMS II) was a 2-year placebo-controlled clinical study in 728 multiple sclerosis patients treated with fingolimod (placebo: 355).
Ispitivanje D2309 (FREEDOMS II) bilo je 2-godišnje placebom kontrolirano kliničko ispitivanje u 728 bolesnika s multiplom sklerozom liječenih fingolimodom (placebo: 355).
Study data indicate that Asian patients may be more susceptible to liver function test abnormalities - 3.2% (194/5995) of Asian patients and 1.8% (100/5641) of Caucasian patients.
Podaci iz ispitivanja ukazuju na to da bolesnici azijskog podrijetla mogu biti skloniji poremećajima vrijednosti testova funkcije jetre - 3,2% (194/5995) bolesnika azijskog podrijetla i 1,8% (100/5641) bijelaca.
Study days, injection of lipegfilgrastim at day 0
Dani ispitivanja, injekcija lipegfilgrastima 0. dana
Study design
Dizajn studije
Study design with a: indacaterol 150 microgram, salmeterol and placebo; b: indacaterol 150 and 300 microgram, tiotropium and placebo; c: indacaterol 300 microgram, formoterol and placebo
Dizajn ispitivanja s a: indakaterolom u dozi od 150 mikrograma, salmeterolom i placebom; b: indakaterolom u dozi od 150 i 300 mikrograma, tiotropijem i placebom; c: indakaterolom u dozi od 300 mikrograma, formoterolom i placebom
Study E2100 (paclitaxel)
Ispitivanje E2100 (paklitaksel)
Study E3200 used a 5 mg/kg/week equivalent dose of bevacizumab in bevacizumab-naïve patients, while study ML18147 used a 2.5 mg/kg/week equivalent dose of bevacizumab in bevacizumab- pretreated patients.
U ispitivanju E3200 je u bolesnika koji prethodno nisu bili liječeni bevacizumabom primijenjena doza bevacizumaba ekvivalentna dozi od 5 mg/kg na tjedan, dok je u ispitivanju ML18147 u bolesnika prethodno liječenih bevacizumabom primijenjena doza bevacizumaba ekvivalentna dozi od 2,5 mg/kg na tjedan.
Study ENB-002-08/ENB-003-08
Ispitivanje ENB-002-08/ENB-003-08
Study ENB-002-08/ENB-003-08 was an open-label, non-randomised, non-controlled study.
Ispitivanje ENB-002-08/ENB-003-08 bilo je nerandomizirano, nekontrolirano ispitivanje otvorenog tipa.
Study ENB-006-09/ENB-008-10 was an open-label, non-randomised study.
Ispitivanje ENB-006-09/ENB-008-10 bilo je nerandomizirano ispitivanje otvorenog tipa.
Study Endpoint
Ishod ispitivanja
Study endpoint
Krajnji ishod ispitivanja
Study FVF2598g (MARINA)
Ispitivanje FVF2587g (ANCHOR)
Study G2301 was a randomised, double-blind, placebo-controlled withdrawal study of flare prevention by Ilaris.
Ispitivanje G2301 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje sprječavanja naglih pogoršanja Ilarisom s fazom ustezanja aktivne terapije.
Study G2305 was a randomised, double-blind, placebo-controlled, 4-week study assessing the short- term efficacy of Ilaris in 84 patients randomised to receive a single dose of 4 mg/kg (up to 300 mg) Ilaris or placebo.
Ispitivanje G2305 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano, 4-tjedno ispitivanje kojim se ocjenjivala kratkoročna djelotvornost Ilarisa u 84 bolesnika randomiziranih na primanje jednokratne doze od 4 mg/kg (do 300 mg) Ilarisa ili placeba.
Study GS-US-236-0102
Ispitivanje GS-US-236-0102
Study GS-US-236-0103
Ispitivanje GS-US-236-0103
Study GS-US-264-0106: Of the 469 Eviplera-treated patients [317 patients who switched to Eviplera at baseline (Eviplera arm) and 152 patients who switched at week 24 (Delayed Switch arm)], a total of
Ispitivanje GS-US-264-0106: Od 469 pacijenata liječenih lijekom Eviplera [317 pacijenata prebačenih na lijek Eviplera na početku (skupina na lijeku Eviplera) i 152 pacijenta koji su se prebacili u
Study GS-US-264-0106: The efficacy and safety of switching from a ritonavir-boosted PI in combination with two NRTIs to FTC/RPV/TDF was evaluated in a randomised, open-label study in virologically suppressed HIV-1 infected adults.
Ispitivanje GS-US-264-0106: Djelotvornost i sigurnost prebacivanja sa PI (protease inhibitor) pojačanog ritonavirom u kombinaciji s dva NRTI-a na FTC/RPV/TDF ocijenjeni su u otvorenom randomiziranom ispitivanju u odraslih zaraženih HIV-1 kod kojih je virus bio suprimiran.
Study GS-US-264-0111: Through Week 48, no emergent resistance developed among patients that switched to FTC/RPV/TDF from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) (0 of 49 patients).
Ispitivanje GS-US-264-0111: Tijekom 48. tjedna među bolesnicima koji su se prebacili na FTC/RPV/TDF sa efavirenza/emtricitabina/tenofovirdizoproksilfumarata (EFV/FTC/TDF) nije se razvila nikakva novonastala rezistencija (0 od 49 bolesnika).
Study GS-US-264-0111: Through week 48, no emergent resistance developed in the 2 patients that failed virologically among patients that switched to Eviplera from efavirenz/emtricitabine/tenofovir disoproxil (0 of 49 patients).
Ispitivanje GS-US-264-0111: Do 48. tjedna, rezistencija na liječenje nije se razvila u 2 pacijenta s virološkim neuspjehom među pacijentima koji su s efavirenza/emtricitabina/tenofovirdizoproksila bili prebačeni na lijek Eviplera (0 od 49 pacijenata).
Study HPC2014 N = 43
Ispitivanje HPC2014 N = 43
Study HPC3006 was an open-label, Phase 3b study in treatment- naïve and treatment-experienced chronic genotype 1 HCV- infected patients who were first time liver transplant recipients and were on a stable regimen of the immunosuppressants tacrolimus or cyclosporine A. No patients had cirrhosis of the liver graft.
Ispitivanje HPC3006 bilo je otvoreno ispitivanje faze 3b, u bolesnika s kroničnom infekcijom HCV genotipa 1 koji prethodno nisu bili liječeni i u prethodno liječenih bolesnika kojima je prvi put transplantirana jetra, te su bili na stabilnom režimu liječenja s imunosupresivima takrolimusom ili ciklosporinom A. Niti jedan bolesnik nije imao cirozu transplantirane jetre.
Study HPC3008
Ispitivanje 106 i Ispitivanje 107
Study HPC3021 N = 40
Ispitivanje HPC3021 N = 40
Study I
Ispitivanje I
Study I AMBITION
Ispitivanje I AMBITION
Study I compared the efficacy of each of 2 prophylactic treatment regimens (fixed weekly interval and individualised interval) to on demand treatment.
Ispitivanje I usporedilo je djelotvornost 2 profilaktička režima liječenja (fiksni tjedni interval i individualizirani interval) s liječenjem prema potrebi.
Study I compared the efficacy of each of 2 prophylactic treatment regimens (individualised and weekly) to on demand treatment.
Ispitivanje I usporedilo je djelotvornost 2 profilaktička režima liječenja (individualizirani i tjedni) s liječenjem prema potrebi.
Study I evaluated 673 patients who had not been treated with MTX within six months prior to randomisation and who had not discontinued previous MTX treatment as a result of clinically important toxic effects or lack of response.
Ispitivanje I uključilo je analizu 673 bolesnika koji nisu bili liječeni MTX-om tijekom šest mjeseci prije randomizacije i koji nisu prekinuli prethodno liječenje MTX-om zbog klinički značajnih toksičnih učinaka ili izostanka terapijskog odgovora.
Study I patients were randomized to receive abatacept 2 or 10 mg/kg or placebo for 12 months.
U Ispitivanju I bolesnici su randomizirani da tijekom 12 mjeseci primaju abatacept u dozi od 2 ili 10 mg/kg, odnosno placebo.
Study I*
Ispitivanje I
Study I: Daily On time (h)
Ispitivanje I: dnevno trajanje „ON“ faze (sati)
Study II enrolled a total of 30 previously treated male pediatric patients with severe hemophilia B (≤ 2% endogenous FIX activity).
Ispitivanje II uključilo je ukupno 30 prethodno liječenih muških pedijatrijskih bolesnika s teškom hemofilijom B (≤2% aktivnosti endogenog FIX).
Study II enrolled a total of 71 previously treated male paediatric patients with severe haemophilia A. Of the 71 enrolled subjects, 69 received at least 1 dose of ELOCTA and were evaluable for efficacy.
Ispitivanje II uključilo je ukupno 71 prethodno liječenog pedijatrijskog bolesnika s teškom hemofilijom A. Od 71 uključenog ispitanika, 69 je primilo najmanje 1 dozu lijeka ELOCTA i u njih se mogla procijeniti djelotvornost.
Study II, a two year study with planned analyses at week 24, week 52 and week 104, evaluated 1,196 patients who had an inadequate clinical response to MTX.
Ispitivanje II, u trajanju od dvije godine s planiranim analizama u 24., 52. i 104. tjednu, uključilo je 1196 bolesnika s neprimjerenim kliničkim odgovorom na MTX.
Study II: Proportion of daily On time (%)
Ispitivanje II: udio dnevnog trajanja „ON“ faze (%)
Study in animals has shown effects on semen parameters, without a significant impact on reproductive performance in males and reduction on the percentage of live foetuses in treated females (see section 5.3).
Ispitivanja na životinjama pokazala su učinak na parametre sjemena, bez značajnog utjecaja na reproduktivnu sposobnost u mužjaka i smanjenje postotka živih fetusa u liječenih ženki (vidjeti dio 5.3).
Study in children/adolescents aged 1 – 18 years with de novo ALL
Ispitivanja u djece/adolescenata u dobi od 1 do 18 godina s de novo ALL-om
Study in patients switching from agalsidase beta to Replagal (agalsidase alfa)
Ispitivanje u bolesnika koji su prešli s agalzidaze beta na Replagal (agalzidazu alfa)
Study in patients switching from imiglucerase treatment to VPRIV
Ispitivanje na bolesnicima koji su prešli s liječenja imiglucerazom na VPRIV
Study in subjects with a history of major depressive disorder
Ispitivanje s ispitanicima s velikim depresivnim poremećajem:
Study IV did not require any specific number of tender or swollen joints.
U Ispitivanju IV nije se tražio određen broj bolnih ili otečenih zglobova.
Study IV primarily assessed safety in patients with active rheumatoid arthritis requiring additional intervention in spite of current therapy with non-biological and/or biological DMARDs; all DMARDs used at enrollment were continued.
Ispitivanje IV je prvenstveno ocjenjivalo sigurnost u bolesnika s aktivnim reumatoidnim artritisom kojima je bila potrebna dodatna intervencija usprkos postojećoj terapiji nebiološkim i/ili biološkim DMARD-ima, a bolesnici su nastavili uzimati sve DMARD-e koje su koristili u trenutku uključivanja u ispitivanje.
Study JO25567 was a randomized, open-label, multi-center Phase II study conducted in Japan to evaluate the efficacy and safety of Avastin used in addition to erlotinib in patients with non-squamous NSCLC with EGFR activating mutations (exon 19 deletion or exon 21 L858R mutation) who had not received prior systemic therapy for Stage IIIB/IV or recurrent disease.
Ispitivanje JO25567 bilo je randomizirano, otvoreno, multicentrično ispitivanje faze II, provedeno u Japanu s ciljem utvrđivanja djelotvornosti i sigurnosti lijeka Avastin kao dodatka erlotinibu u bolesnika oboljelih od neskvamoznog NSCLC-a s aktivirajućim mutacijama EGFR-a (delecija eksona 19 ili mutacija L858R u eksonu 21) koji prethodno nisu primali sistemsku terapiju za bolest stadija IIIB/IV ili recidivirajuću bolest.
Study LEVP 2005-1/A used a randomised, double-blind, placebo-controlled, parallel group design; 71 subjects with acute HAE attacks were randomised (36 Cinryze, 35 placebo).
Ispitivanje LEVP 2005-1/A bilo je ustrojeno kao randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje na usporednim skupinama; bio je randomiziran 71 ispitanik s akutnim napadajima HAE (36 Cinryze, 35 placebo).
Study LEVP 2005-1/B used a randomised, double-blind, placebo-controlled, crossover design; 22 subjects were evaluable for efficacy (randomised and treated in both crossover periods).
Ispitivanje LEVP 2005-1/B bilo je ustrojeno kao randomizirano, dvostruko slijepo, placebom kontrolirano ukriženo ispitivanje; djelotvornost se mogla procijeniti u 22 ispitanika (randomizirani i liječeni u oba razdoblja ukriženog ispitivanja).
Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (BR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV).
Ispitivanje LYM 3002 bilo je randomizirano, otvoreno ispitivanje faze III koje je uspoređivalo djelotvornost i sigurnost kombinacije bortezomiba, rituksimaba, ciklofosfamida, doksorubicina i prednizona (BR-CAP; n=243) s kombinacijom rituksimaba, ciklofosfamida, doksorubicina, vinkristina, i prednizona (R-CHOP; n=244) u odraslih bolesnika s prethodno neliječenim limfomom plaštenih stanica (Stadij II, III ili IV).
Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (BzmbR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV).
Ispitivanje LYM-3002 bilo je randomizirano, otvoreno ispitivanje faze III koje je uspoređivalo djelotvornost i sigurnost kombinacije bortezomiba, rituksimaba, ciklofosfamida, doksorubicina i prednizona (BzmbR-CAP; n=243) s onima kombinacije rituksimaba, ciklofosfamida, doksorubicina, vinkristina, i prednizona (R-CHOP; n=244) u odraslih bolesnika s prethodno neliječenim limfomom plaštenih stanica (Stadij II, III ili IV).
Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (BzR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV).
Ispitivanje LYM 3002 bilo je randomizirano, otvoreno ispitivanje faze III koje je uspoređivalo djelotvornost i sigurnost kombinacije bortezomiba, rituksimaba, ciklofosfamida, doksorubicina i prednizona (BzR-CAP; n=243) s onima kombinacije rituksimaba, ciklofosfamida, doksorubicina, vinkristina, i prednizona (R-CHOP; n=244) u odraslih bolesnika s prethodno neliječenim limfomom plaštenih stanica (Stadij II, III ili IV).
Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV).
Ispitivanje LYM 3002 bilo je randomizirano, otvoreno ispitivanje faze III koje je uspoređivalo djelotvornost i sigurnost kombinacije VELCADEa, rituksimaba, ciklofosfamida, doksorubicina i prednizona (VcR-CAP; n = 243) s onima kombinacije rituksimaba, ciklofosfamida, doksorubicina, vinkristina, i prednizona (R-CHOP; n = 244) u odraslih bolesnika s prethodno neliječenim limfomom plaštenih stanica (Stadij II, III ili IV).
Study M05-730 was a randomised, open-label, multicentre trial comparing treatment with Kaletra 800/200 mg once daily plus tenofovir DF and emtricitabine versus Kaletra 400/100 mg twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral treatment-naïve patients.
Studija M05-730 je bila randomizirano, otvoreno (''open-label''), multicentrično ispitivanje u kojem se uspoređivalo liječenje lijekom Kaletra 800/200 mg jednom dnevno plus tenofovir DF i emtricitabin nasuprot lijeka Kaletra 400/100 mg dva puta dnevno plus tenofovir DF i emtricitabin, u 664 bolesnika koji prethodno nisu koristili antiretrovirusnu terapiju.
Study M05-730 was a randomised, open-label, multicentre trial comparing treatment with lopinavir/ritonavir 800/200 mg once daily plus tenofovir DF and emtricitabine versus lopinavir/ritonavir 400/100 mg twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral treatment-naïve patients.
Studija M05-730 je bila randonimizirano, otvoreno (''open-label''), multicentrično ispitivanje, u kojem se uspoređivalo liječenje lopinavirom/ritonavirom 800/200 mg jednom dnevno plus tenofovir DF i emtricitabinom naspram lopinavira/ritonavira 400/100 mg dva puta dnevno plus tenofovir DF i emtricitabin u 664 bolesnika koji prethodno nisu koristili antiretrovirusnu terapiju.
Study M98-863 was a randomised, double-blind trial of 653 antiretroviral treatment naïve patients investigating Kaletra (400/100 mg twice daily) compared to nelfinavir (750 mg three times daily) plus stavudine and lamivudine.
Studija M98-863 bila je randomizirano, dvostrukoslijepo ispitivanje lijeka Kaletra (400/100 mg dvaput na dan) u usporedbi s nelfinavirom (750 mg triput na dan) plus stavudin i lamivudin u 653 bolesnika bez prethodne antiretrovirusne terapije.
Study M98-863 was a randomised, double-blind trial of 653 antiretroviral treatment naïve patients investigating lopinavir/ritonavir (400/100 mg twice daily) compared to nelfinavir (750 mg three times daily) plus stavudine and lamivudine.
Studija M98-863 bila je randomizirano, dvostrukoslijepo ispitivanje lopinavira/ritonavira (400/100 mg dvaput na dan) u usporedbi s nelfinavirom (750 mg triput na dan) plus stavudin i lamivudin u 653 bolesnika bez prethodne antiretrovirusne terapije.
Study MB102129
Ispitivanje MB102129
Study MEK116513 was a 2-arm, randomised, open-label, Phase III study comparing dabrafenib and trametinib combination therapy with vemurafenib monotherapy in BRAF V600 mutation-positive metastatic melanoma.
Ispitivanje MEK116513 bilo je randomizirano, otvoreno ispitivanje faze III s 2 skupine u kojem se uspoređivala kombinirana terapija dabrafenibom i trametinibom s monoterapijom vemurafenibom kod metastatskog melanoma s pozitivnom BRAF V600 mutacijom.
Study MenACWY-
Ispitivanje MenACWY
Study MenACWY-TT-039(1)
Ispitivanje MenACWY-TT-039 (1)
Study MenACWY-TT-040(2)
Ispitivanje MenACWY-TT-040 (2)
Study MenACWY-TT-104(1)
Ispitivanje MenACWY-TT-104 (1)
Study MenACWY-TT-104(1)
Studija MenACWY-TT-104(1)
Study MN301 randomised 358 subjects with active rheumatoid arthritis to leflunomide 20 mg/day (n=133), sulphasalazine 2 g/day (n=133), or placebo (n=92).
U studiji MN301 358 randomiziranih bolesnika s aktivnim reumatoidnim artritisom uzimalo je leflunomid 20 mg/dan (n=133), sulfasalazin 2 g/dan (n=133) ili placebo (n= 92).
Study MN303 was an optional 6-month blinded continuation of MN301 without theplacebo arm, result ing in a 12-month comparison of leflunomide and sulphasalazine.
Studija MN303 bila je neobavezni slijepi 6-mjesečni nastavak studije MN301 bez placeba, što je rezultiralo 12-mjesečnom usporedbom leflunomida i sulfasalazina.
Study MO16982: loading dose 6 mg/kg weekly x 3; followed by 6 mg/kg 3-weekly schedule
Ispitivanje MO16982: udarna doza 6 mg/kg tjedno kroz 3 tjedna, zatim 6 mg/kg u trotjednim ciklusima
Study MO22982 investigated switching between the Herceptin intravenous and Herceptin subcutaneous formulation with a primary objective to evaluate patient preference for either intravenous or the subcutaneous route of trastuzumab administration.
U ispitivanju MO22982 istraživao se prelazak s intravenske formulacije lijeka Herceptin na supkutanu formulaciju lijeka Herceptin i obrnuto, a primarni je cilj bio ocijeniti daju li bolesnici prednost intravenskom ili supkutanom putu primjene trastuzumaba.
Study MV17150
Ispitivanje MV17150
Study N01358
Ispitivanje br.
Study NB-302 had a more intensive behavioural modification program, while the primary endpoint of Study NB-303 was at Week 28 to allow for re-randomization to different doses in the latter portion of the study.
Ispitivanje NB-302 je imalo intenzivniji program promjene ponašanja, dok je primarni ishod ispitivanja NB-303 bio 28. tjedan kako bi se omogućila ponovna randomizacija na druge doze u kasnijem dijelu ispitivanja.
Study No.
Br. ispitivanja
Study No.
Ispitivanje br.
Study NR15961
Ispitivanje NR15961
Study Number/ Treatment Regimensb
Broj ispitivanja/ Protokoli liječenjab
Study Number/ Treatment Regimensb
Broj ispitivanja/ Režimi liječenjab
Study NV15942
Ispitivanje NV15492
Study of sitagliptin in combination with metformin and a PPAR agonist
Ispitivanje sitagliptina u kombinaciji s metforminom i agonistom PPAR
Study of sitagliptin in combination with metformin and a sulphonylurea
Ispitivanje sitagliptina u kombinaciji s metforminom i sulfonilurejom
Study of sitagliptin in combination with metformin and insulin
Ispitivanje sitagliptina u kombinaciji s metforminom i inzulinom
Study participants
Ispitanici
Study performed with
Ispitivanje je provedeno s
Study performed with
Ispitivanje je provedeno s amprenavirom.
Study population
Populacija uključena u ispitivanje
Study population
Studijska populacija
Study protocols
Planove ispitivanja
Study protocols to be submitted by September
PASS će započeti
Study RA-I Methotrexate combination (24 and 52 weeks)
Ispitivanje RA-I Kombinacija s metotreksatom (24 i 52 tjedna)
Study Report:
ispitivanju:
Study results Study GOG-0179
Rezultati ispitivanja studije GOG-0179
Study results Study GOG-0179
Rezultati studije GOG-0179
Study S2 (105) evaluated patients who were splenectomised and continued to have thrombocytopenia.
U ispitivanje S2 (105) uključeni su bolesnici koji nakon splenektomije i dalje imaju trombocitopeniju.
Study SC-I compared the immunogenicity to abatacept following subcutaneous or intravenous administration as assessed by ELISA assay.
U Ispitivanju SC-I uspoređivala se imunogenost na abatacept nakon supkutane odnosno intravenske primjene, primjenom ELISA testa.
Study SC-I compared the safety of abatacept including injection site reactions following subcutaneous or intravenous administration.
U Ispitivanju SC-I uspoređivala se sigurnost primjene abatacepta, uključujući reakcije na mjestu injekcije nakon supkutane odnosno intravenske primjene.